WuXi Bids Farewell To US Listing As It Vows To ‘Revolutionize R&D’
This article was originally published in PharmAsia News
Being a private company affords WuXi to be more focused on chasing its new drug R&D dream, says the contract clinical research-focused group. But many see a relisting of the company before too long, this time on China's A-share market rather than in the US, in a pattern already established by several other Chinese firms.
You may also be interested in...
BeiGene's BTK inhibitor for leukemia/lymphoma and Sanofi/Genzyme's enzyme replacement therapy for MPS I among novel drugs newly approved in China.
In a key step to prop up traditional Chinese medicines, Beijing has proposed a law that could potentially punish any vocal doubters. The move signals a familiar pattern as China resorts to using old approaches when facing a flurry of new challenges.
Facing the aftermath of coronavirus disruption and supply chain reorganization, executives of multinational drug firms in China say the government needs to do more to help address a flurry of issues laid bare by the public health crisis.